Aaron Ondrey
Directeur Financier/CFO chez ROCKET PHARMACEUTICALS, INC.
Fortune : 1 M $ au 30/04/2024
Profil
Aaron Ondrey is currently the Chief Financial Officer at Rocket Pharmaceuticals, Inc. He previously worked as the Executive Director-Commercial Finance at Regeneron Pharmaceuticals, Inc. from 2010 to 2018.
Additionally, he served as the Chief Financial Officer & SVP-Financial Planning at Mirati Therapeutics, Inc. from 2022 to 2024.
Mr. Ondrey obtained his undergraduate degree from Case Western Reserve University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/04/2024 | 46 781 ( 0,05% ) | 1 M $ | 30/04/2024 |
Postes actifs de Aaron Ondrey
| Sociétés | Poste | Début |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Directeur Financier/CFO | 26/03/2024 |
Anciens postes connus de Aaron Ondrey
| Sociétés | Poste | Fin |
|---|---|---|
| MIRATI THERAPEUTICS | Directeur Financier/CFO | 23/01/2024 |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/11/2018 |
Formation de Aaron Ondrey
| Case Western Reserve University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
